-
2 months ago | 
timesofsandiego.com | David Jensen
California scientists took what looked like an $800 million hit last week in their efforts to develop revolutionary treatments and cures for diseases ranging from cancer to diabetes. It was a jab from the Trump administration, one that generated apocalyptic predictions and mind-numbing jargon about paying bills for janitors, water, electricity, computer support and hazardous waste disposal, among other things. “Lights in Labs Nationwide Will Literally Go Out” warned one headline.
-
2 months ago | 
capitolweekly.net | David Jensen
News by DAVID JENSEN posted 02.19.2025 California scientists took what looked like an $800 million hit last week in their efforts to develop revolutionary treatments and cures for diseases ranging from cancer to diabetes.
-
2 months ago | 
jensendavid.substack.com | David Jensen
The cost to borrow Spider Gold ‘GLD’ Exchange Traded Fund (ETF) shares has almost tripled in 5 hours today to 6.29%. In mid-January 2025, the borrow fee for GLD shares was 0.5%. ‘Authorized Participants’, as defined by the GLD prospectus and consisting primarily of bullion banks, can redeem ‘Baskets’ of GLD shares to receive delivery of 10,000 oz. of gold at a time.
-
2 months ago | 
jensendavid.substack.com | David Jensen
In the weeks and months ahead, there is going to be considerable discussion about the cash markets for gold and silver becoming ‘disorderly’. In reality what will be happening is order being restored to the cash/spot price discovery of physical gold and silver market after decades of rigged price setting in London utilizing London’s cash market promissory note metal pricing system.
-
2 months ago | 
capitolweekly.net | David Jensen
News Smoke blanketing California's coastline. Image courtesy of NOAA website. by DAVID JENSEN posted 01.29.2025 When some Los Angeles area residents returned to homes that survived the wildfires, it felt like they were hit by an “invisible injury.” Their couches, rugs and even walls reeked.
-
2 months ago | 
david293.substack.com | David Jensen
“The Devastating Legacy of Lies in Alzheimer’s Science” read the headline this weekend in the New York Times. “Over the past 25 years, Alzheimer’s research has suffered a litany of ostensible fraud and other misconduct by world-famous researchers and obscure scientists alike, all trying to ascend in a brutally competitive field,” said the essay by Charles Piller.
-
Dec 15, 2024 | 
stocktonia.org | David Jensen
California’s $12 billion stem cell experiment turned 20 years old this fall, winning kudos from some patients and scientists but failing to fulfill the expectations of voters who thought they had created an enterprise that would lead quickly to revolutionary cures for cancer, heart disease, stroke and much more. It was a grand dream in 2004 when Californians voted overwhelmingly to establish the California Institute for Regenerative Medicine, or CIRM, in response to then-President George W.
-
Dec 5, 2024 | 
capitolweekly.net | David Jensen
News Scientist performing stem cell research for cancer therapy.
-
Oct 26, 2024 | 
scholarsarchive.byu.edu | David Jarvis |David Jensen |Fernando Fonseca |Brigham Young
Keywordsrectangular carbon fiber IsoTruss, concrete beams, flexural strengthCollegeIra A. Fulton College of Engineering and TechnologyDepartmentCivil and Environmental EngineeringAbstractThe objective of this research was to determine the flexural strength of concrete beams reinforced by the rectangular carbon fiber IsoTruss. The rectangular IsoTruss is a threedimensional composite grid structure patented by Brigham Young University.
-
Oct 3, 2024 | 
digitalcommons.library.tmc.edu | David Jensen |Peng Han |Lingegowda S. Mangala |Gabriel Lopez-Berestein
AbstractMicroRNA miR-29 promotes endothelial function in human arterioles in part by targeting LYPLA1 and increasing nitric oxide production. In addition, miR-29 is a master inhibitor of extracellular matrix gene expression, which may attenuate fibrosis but could also weaken tissue structure. The goal of this study was to test whether miR-29 could be developed as an effective, broad-acting, and safe therapeutic.
